The purpose of this prospective clinical data collection is to compare the outcomes of two
different tibial bearings: the Maxim® Pop-Top® Tibia and Maxim® Modular Tibia.
The purpose of this prospective clinical data collection is to document and compare the
performance and clinical outcomes between the Maxim® Knee System with Removable Molded Poly
Tibia and the Maxim® Knee System with Modular Tibial Bearing as two treatment groups.
FDA has cleared these devices via Premarket Notification 510(k)'s K991753, K984623, K993159,
K010027. The data gathered will be collated and used to provide feedback to designing
engineers, support marketing efforts and answer potential questions from reimbursement
Identical to the indications stated in the FDA approved labeling for the device (cleared
in 510(k) K991753,
K984623, K993159, K010027). These indications are stated below:
- Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis,
traumatic arthritis where one or more compartments are involved.
- Correction of varus, valgus, or posttraumatic deformity.
- Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous
joint replacement procedure.
Patient selection factors to be considered include:
- need to obtain pain relief and improve function,
- ability and willingness of the patient to follow instructions, including control of
weight and activity level,
- a good nutritional state of the patient,
- the patient must have reached full skeletal maturity.
- Porous coated knee joint replacement prostheses have not been approved for
non-cemented applications in the United States.
Identical to the contraindications stated in the FDA approved labeling for the device
(cleared in 510(k) K991753, K984623, K993159, K010027's). These contraindications are
Absolute contraindications include:
Relative contraindications include:
- uncooperative patient or patient with neurologic disorders who are incapable of
- metabolic disorders which may impair bone formation,
- distant foci of infections which may spread to the implant site,
- rapid joint destruction, marked bone loss or bone resorption apparent on
- vascular insufficiency, muscular atrophy, neuromuscular disease,
- incomplete or deficient soft tissue surrounding the knee.